Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of Pulsed GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2021
Price :
$35
*
At a glance
- Drugs GRF-6019 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Alkahest
- 09 Jul 2020 According to an Alkahest media release, additional biomarker analyses for this study is ongoing.
- 20 May 2020 Status changed from active, no longer recruiting to completed.
- 29 Jan 2020 Status changed from recruiting to active, no longer recruiting.